Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis

Figure 3

miR-125b as predictive biomarker for rituximab treatment outcome in RA. (a) DAS28 M3-M0 represents the difference at baseline versus 3 months after rituximab treatment. Patients were considered nonresponders (NR, 𝑛=16) or responders (R, 𝑛=16) according to EULAR criteria. Serum mature miR-125b (b), miR-142-3p (c), and miR-142-5p (d) are quantified in RA patients according to their clinical response. ^∗𝑃<0.05, ^∗∗𝑃<0.01 as determined by Mann-Whitney test.

(a)

(b)

(c)

(d)